The University of Barcelona uses the acquisition of Enantia by Inveready to disinvest in the spin-off company
The University of Barcelona has completed the disinvestment of Enantia, one of the most prominent spin-offs in the field of pharmaceutical chemistry. It has done so on the occasion of the sale of this company to Inveready, one of Spain’s leading venture capital funds. This is the first time that an operation of this kind has been carried out at the UB. It is a step forward in the UB’s strategy to promote the development of technology transfer.
Further information
The University of Barcelona has completed the disinvestment of Enantia, one of the most prominent spin-offs in the field of pharmaceutical chemistry. It has done so on the occasion of the sale of this company to Inveready, one of Spain’s leading venture capital funds. This is the first time that an operation of this kind has been carried out at the UB. It is a step forward in the UB’s strategy to promote the development of technology transfer.
Further information